A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 该方案的主要目的是比较非类固醇免疫抑制联合他克莫司(Prograf)、霉酚酸酯(CellCept)和达克珠单抗(Zenapax)诱导与类固醇免疫抑制的安全性和有效性。 他克莫司/MPAPK分组研究的具体目的是确定他克莫司和霉酚酸酯在纳入SNS01方案的儿童肾移植患者中的生物利用度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: The primary objective of this protocol is to compare the safety and efficacy of steroid-free immunosuppression, given in combination with tacrolimus (Prograf), mycophenolate mofetil (CellCept) and daclizumab (Zenapax) induction with steroid-based immunosuppression. The specific aim of the tacrolimus/MPA PK sub-study is to determine the bioavailability of tacrolimus and mycophenolate mofetil in pediatric renal transplant patients enrolled in Protocol SNS01.